Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yellow Fever Vaccine Immunity in HIV Patients (NovaaTen)
NCT05450770Not yet recruiting
- Sponsor
- ANRS
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Live Attenuated Vaccines
01
Overview
Open-label trial of 17D yellow fever vaccine in yellow fever (2 arms), sponsored by ANRS. Primary endpoint: Immuno-virologic criterion (Neutralizing antibody titers) at 10 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT05450770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450770.